Download Your Exclusive Copy of the Agenda
Oligonucleotide R&D is accelerating rapidly, with billion-dollar investment from Novartis, Biogen and Roche signalling a clear shift toward CNS applications. For the first time, oligo therapeutics are enabling access to previously undruggable CNS targets - with emerging clinical success beginning to validate their potential.
This year’s program reflects that shift.
Download the Full Event Guide to Discover:
Who’s Speaking
Senior Experts from Pharma, Biotech & Leading CNS Oligo Innovators
Networking Opportunities
Targeted Connections with Scientists & Decision-Makers across CNS & RNA
What’s New for 2026
Latest on Delivery, RNA Chemistry & Clinical Translation
Partnership Packages
Showcase Your Solutions to Teams Advancing CNS Oligo Pipelines
Key Industry Themes
CNS Delivery, BBB Access, PK/PD, Safety & Target Discovery
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Attending Companies Include
